About us

Company >

Over the last 50 years, IMS has invested on R&D, Production and Quality Management, working together with radiologists and radiographers to improve image quality and simplify procedures, with the outcome of the most advanced breast imaging technology. Thanks to this continuous commitment, early detection of breast cancer is now achievable around the world, improving women’s health.

IMS GIOTTO is constantly engaged in the research and development of the latest technologies in breast imaging field.
The high quality and excellent clinical performance of our products are the result of continuous controls along the whole process, from software design and hardware manufacturing to the final product.

Mission and Vision >

We use our many decades of experience in diagnostic imaging technologies all through our continuous research and testing of mammography systems to drive the evolution of the technology designed and produced by IMS Giotto.

Our greatest ambition is to produce high-performance systems that aid clinicians in the timely detection and accurate diagnosis of breast lesions anywhere in the world, ultimately serving the healthcare of women.

History >

1965
1985
2003
2007
2011
2013
2015
2017
2018
2018
2021
2021

1965

1965

IMS – INTERNAZIONALE MEDICO SCIENTIFICA S.r.l. was born thanks to the initiative of Mr. Bruno Toniolo, the founder. From the very beginning the Company established itself also in the X-ray products and conventional radiography units.

1965

1985

1985

IMS founded a dedicated R&D department to design the first mammography system; in only a few years IMS grew and became one of the leading names in mammography field.

1985

2003

2003

IMS marketed the first Full Field Digital Mammography unit made in Europe, which has continuously evolved through the years and became GIOTTO IMAGE 3DL: an outstanding mammography unit combining the traditional ring-shaped gantry, for better access, with the most advanced generation of Amorphous Selenium detector.
The combination with the Mammobed unit created a 2-in-1 system for mammography and prone biopsy using the same detector.

2003

2007

2007

IMS began to investigate Tomosynthesis technology and was the first company to explore the technological approach of using the Step and Shoot Scan, variable angle and variable dose.

2007

2011

2011

IMS launched Giotto Tomo, the first mammography unit made by IMS with Digital Breast Tomosynthesis (DBT), optimized to provide excellent image quality with a low dose.

2011

2013

2013

IMS improved the Giotto Tomo system offering a more performing detector and an improved “combo” modality. New and old systems could then be equipped with CANOVA, a proprietary iterative reconstruction algorithm.

2013

2015

2015

IMS was successful in the creation of a unit combining Mammography, Tomosynthesis and (prone) Biopsy: the Giotto Class, whose unicity is granted by international patents and greatly appreciated around the world.

2015

2017

2017

IMS GIOTTO S.P.A. was born as part of the GENERAL MEDICAL MERATE S.P.A. group, a well-known operator in the diagnostic radiology sector, based in Seriate (Bergamo), of which Mr. Massimo Sordi is Chairman.


A new variant was added to the CLASS systems portfolio, with the same imaging performances but with a compact design and fast operation for optimal screening workflow: the Giotto Class S.

2018

2018

A new modality was introduced in the multi-purpose Giotto Class: contrast enhanced mammography (CEM) became possible with a software upgrade.

2018

2018

2018

IMS Giotto adds to the products portfolio its first in-vitro diagnostic medical device: Smart Checker, for the safe storage and imaging of the breast biopsy samples.
With this accessory the versatility of Giotto CLASS is further enriched.

2018

2021

2021

Two new categories of medical devices are added to IMS GIOTTO Class products:
Raffaello, as a stand-alone medical software
Raffaello Plus: a digitalization retrofit kit for radiological equipment, powered by Raffaello.

2021

2021

2021

IMS Giotto never rests and will soon bring breast imaging into the future thanks to AI integration and CEM-guided biopsy.

2021

Other Insights >

PRESIDENT

QUALITY

PATENTS

R&D AND PRODUCTION